These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26621701)

  • 1. ADP-stimulated contraction: A predictor of thin-filament activation in cardiac disease.
    Sequeira V; Najafi A; Wijnker PJ; Dos Remedios CG; Michels M; Kuster DW; van der Velden J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):E7003-12. PubMed ID: 26621701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
    Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy.
    Witjas-Paalberends ER; Piroddi N; Stam K; van Dijk SJ; Oliviera VS; Ferrara C; Scellini B; Hazebroek M; ten Cate FJ; van Slegtenhorst M; dos Remedios C; Niessen HW; Tesi C; Stienen GJ; Heymans S; Michels M; Poggesi C; van der Velden J
    Cardiovasc Res; 2013 Aug; 99(3):432-41. PubMed ID: 23674513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
    van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
    Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
    Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
    Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cMyBP-C HCM variant L348P enhances thin filament activation through an increased shift in tropomyosin position.
    Mun JY; Kensler RW; Harris SP; Craig R
    J Mol Cell Cardiol; 2016 Feb; 91():141-7. PubMed ID: 26718724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.
    Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J
    Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
    Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
    J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
    Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac myosin binding protein-C phosphorylation accelerates β-cardiac myosin detachment rate in mouse myocardium.
    Tanner BCW; Previs MJ; Wang Y; Robbins J; Palmer BM
    Am J Physiol Heart Circ Physiol; 2021 May; 320(5):H1822-H1835. PubMed ID: 33666504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy.
    McNamara JW; Li A; Lal S; Bos JM; Harris SP; van der Velden J; Ackerman MJ; Cooke R; Dos Remedios CG
    PLoS One; 2017; 12(6):e0180064. PubMed ID: 28658286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific phosphorylation of myosin binding protein-C coordinates thin and thick filament activation in cardiac muscle.
    Ponnam S; Sevrieva I; Sun YB; Irving M; Kampourakis T
    Proc Natl Acad Sci U S A; 2019 Jul; 116(31):15485-15494. PubMed ID: 31308242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
    van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
    Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myofibrillar force responses to protein kinase A phosphorylation.
    Stelzer JE; Patel JR; Walker JW; Moss RL
    Circ Res; 2007 Aug; 101(5):503-11. PubMed ID: 17641226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
    Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
    J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
    O'Leary TS; Snyder J; Sadayappan S; Day SM; Previs MJ
    J Mol Cell Cardiol; 2019 Feb; 127():165-173. PubMed ID: 30550750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of in vivo left ventricular [correction] contraction/relaxation kinetics by myosin binding protein C: protein kinase A phosphorylation dependent and independent regulation.
    Nagayama T; Takimoto E; Sadayappan S; Mudd JO; Seidman JG; Robbins J; Kass DA
    Circulation; 2007 Nov; 116(21):2399-408. PubMed ID: 17984378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of PKA treatment on the Ca2+ activation of force generation by trout cardiac muscle.
    Gillis TE; Klaiman JM
    J Exp Biol; 2011 Jun; 214(Pt 12):1989-96. PubMed ID: 21613514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac myosin-binding protein C N-terminal interactions with myosin and actin filaments: Opposite effects of phosphorylation and M-domain mutations.
    Wong FL; Bunch TA; Lepak VC; Steedman AL; Colson BA
    J Mol Cell Cardiol; 2024 Jan; 186():125-137. PubMed ID: 38008210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigallocatechin-3-Gallate Accelerates Relaxation and Ca
    Friedrich FW; Flenner F; Nasib M; Eschenhagen T; Carrier L
    Front Physiol; 2016; 7():607. PubMed ID: 27994558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.